A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide
Anagrelide is a medication primarily used to manage thrombocytosis, an abnormal increase in platelet levels in the blood. It is often prescribed for patients with myeloproliferative disorders, such as essential thrombocythaemia (ET). Given the heightened susceptibility to thromboembolism associated...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMC MEDIA SRL
2024-02-01
|
| Series: | European Journal of Case Reports in Internal Medicine |
| Subjects: | |
| Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/4340 |
| _version_ | 1797278807380459520 |
|---|---|
| author | Ekrem Yetiskul Aqsa Nisar Salman Khan Faris Qaqish Danyal Khan Alexander Bershadskiy |
| author_facet | Ekrem Yetiskul Aqsa Nisar Salman Khan Faris Qaqish Danyal Khan Alexander Bershadskiy |
| author_sort | Ekrem Yetiskul |
| collection | DOAJ |
| description | Anagrelide is a medication primarily used to manage thrombocytosis, an abnormal increase in platelet levels in the blood. It is often prescribed for patients with myeloproliferative disorders, such as essential thrombocythaemia (ET). Given the heightened susceptibility to thromboembolism associated with this condition, the primary emphasis in treatment revolves around reducing the risk of thrombotic events through the administration of cytotoxic agents. While anagrelide is generally effective in reducing platelet counts, it comes with potential side effects, including an increased risk of certain thrombotic events. Anagrelide acts by inhibiting megakaryocyte maturation and platelet release, thereby reducing platelet production. However, this platelet-lowering effect may be accompanied by an increase in platelet activation and reactivity, which could contribute to a prothrombotic state. We present a case of a 60-year-old female with a history of ET, managed with anagrelide and hydroxyurea therapy, who experienced an acute ST-elevation myocardial infarction. |
| first_indexed | 2024-03-07T16:14:29Z |
| format | Article |
| id | doaj.art-fb172816d67741c891a7982ae9d5ad22 |
| institution | Directory Open Access Journal |
| issn | 2284-2594 |
| language | English |
| last_indexed | 2024-03-07T16:14:29Z |
| publishDate | 2024-02-01 |
| publisher | SMC MEDIA SRL |
| record_format | Article |
| series | European Journal of Case Reports in Internal Medicine |
| spelling | doaj.art-fb172816d67741c891a7982ae9d5ad222024-03-04T15:29:24ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942024-02-0110.12890/2024_0043403875A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelideEkrem Yetiskul0Aqsa Nisar1Salman Khan2Faris Qaqish3Danyal Khan4Alexander Bershadskiy5Department of Internal Medicine, Staten Island University Hospital, Staten Island, USADepartment of Internal Medicine, Staten Island University Hospital, Staten Island, USADepartment of Internal Medicine, Staten Island University Hospital, Staten Island, USADepartment of Internal Medicine, Staten Island University Hospital, Staten Island, USADepartment of Cardiology, Staten Island University Hospital, Staten Island, USADepartment of Hematology and Oncology, Staten Island University Hospital, Staten Island, USAAnagrelide is a medication primarily used to manage thrombocytosis, an abnormal increase in platelet levels in the blood. It is often prescribed for patients with myeloproliferative disorders, such as essential thrombocythaemia (ET). Given the heightened susceptibility to thromboembolism associated with this condition, the primary emphasis in treatment revolves around reducing the risk of thrombotic events through the administration of cytotoxic agents. While anagrelide is generally effective in reducing platelet counts, it comes with potential side effects, including an increased risk of certain thrombotic events. Anagrelide acts by inhibiting megakaryocyte maturation and platelet release, thereby reducing platelet production. However, this platelet-lowering effect may be accompanied by an increase in platelet activation and reactivity, which could contribute to a prothrombotic state. We present a case of a 60-year-old female with a history of ET, managed with anagrelide and hydroxyurea therapy, who experienced an acute ST-elevation myocardial infarction.https://www.ejcrim.com/index.php/EJCRIM/article/view/4340essential thrombocythaemiaanagrelidemyocardial infarctionthrombosis |
| spellingShingle | Ekrem Yetiskul Aqsa Nisar Salman Khan Faris Qaqish Danyal Khan Alexander Bershadskiy A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide European Journal of Case Reports in Internal Medicine essential thrombocythaemia anagrelide myocardial infarction thrombosis |
| title | A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide |
| title_full | A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide |
| title_fullStr | A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide |
| title_full_unstemmed | A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide |
| title_short | A case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide |
| title_sort | case of acute myocardial infarction in a patient with essential thrombocythaemia treated with anagrelide |
| topic | essential thrombocythaemia anagrelide myocardial infarction thrombosis |
| url | https://www.ejcrim.com/index.php/EJCRIM/article/view/4340 |
| work_keys_str_mv | AT ekremyetiskul acaseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT aqsanisar acaseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT salmankhan acaseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT farisqaqish acaseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT danyalkhan acaseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT alexanderbershadskiy acaseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT ekremyetiskul caseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT aqsanisar caseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT salmankhan caseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT farisqaqish caseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT danyalkhan caseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide AT alexanderbershadskiy caseofacutemyocardialinfarctioninapatientwithessentialthrombocythaemiatreatedwithanagrelide |